Literature DB >> 33971879

Retraction Note to: miR-484 suppresses proliferation and epithelial-mesenchymal transition by targeting ZEB1 and SMAD2 in cervical cancer cells.

Yang Hu1, Hong Xie1, Yankun Liu1, Weiying Liu1, Min Liu1, Hua Tang2.   

Abstract

Entities:  

Year:  2021        PMID: 33971879      PMCID: PMC8108323          DOI: 10.1186/s12935-021-01958-0

Source DB:  PubMed          Journal:  Cancer Cell Int        ISSN: 1475-2867            Impact factor:   5.722


× No keyword cloud information.

Retraction to: Cancer Cell Int (2017) 17:36 https://doi.org/10.1186/s12935-017-0407-9

The Editors-in-Chief have retracted this article [1]. Concerns were raised regarding a number of figures, specifically: Figure 3a: the first and third panel for C33A appear to partially overlap. Figure 3b: panel 2 for C33A appears to partially overlap with panel 2 for C33A in Figure 7b. Figure 7a: panel 1 for HeLa appears to overlap with panel 3 for HeLa in Figure 7b. Figure 7a: panel 3 for C33A appears to partially overlap with panels 4 and 4 for C33A in Figure 7b: panel 6 for HeLa appears to partially overlap with panel 5 for C33A. The Editors-in-Chief therefore no longer have confidence in the reliability of the data reported in the article. All authors agree to this retraction.
  1 in total

1.  miR-484 suppresses proliferation and epithelial-mesenchymal transition by targeting ZEB1 and SMAD2 in cervical cancer cells.

Authors:  Yang Hu; Hong Xie; Yankun Liu; Weiying Liu; Min Liu; Hua Tang
Journal:  Cancer Cell Int       Date:  2017-03-07       Impact factor: 5.722

  1 in total
  1 in total

1.  Use of miRNA Sequencing to Reveal Hub miRNAs and the Effect of miR-582-3p/SMAD2 in the Progression of Hepatocellular Carcinoma.

Authors:  Yi Zhao; Meizhang Li; Nana Miao; Wei Wei; Yulong Dong; Chenjie Tao; Jinzhong Chen; Yongyan Pei; Lieping Guo
Journal:  Front Genet       Date:  2022-03-21       Impact factor: 4.599

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.